dc.contributor
[Ruiz de Porras V, Bystrup S, Cabrero-de Las Heras S] Program of predictive and personalized cancer medicine (PMPPC), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Badalona, Spain. [Musulén E] Department of Pathology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Department of Pathology, Hospital Universitari General de Catalunya, Grupo Quirónsalud, Sant Cugat del Valles, Spain. [Palomero L] Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, L’Hospitalet del Llobregat, Spain. ONCOBELL Program, Bellvitge Institute for Biomedical Research, L’Hospitalet del Llobregat, Spain. [Henar Alonso M] ONCOBELL Program, Bellvitge Institute for Biomedical Research, L’Hospitalet del Llobregat, Spain. Oncology Data Analytics Program, Institut Català d’Oncologia (ICO), Barcelona, Sapin. Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain. Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. [Nieto R, Arango D] Grup de Recerca en Investigació Biomèdica en Tumors de l'Aparell Digestiu, CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Ruiz de Porras, Vicenç
dc.contributor.author
Bystrup, Sara
dc.contributor.author
Cabrero-de Las Heras, Sara
dc.contributor.author
Musulén, Eva
dc.contributor.author
Palomero, Luis
dc.contributor.author
Henar Alonso, Maria
dc.contributor.author
Arango Corro, Diego
dc.contributor.author
Nieto Raya, Rocio
dc.date.accessioned
2025-10-24T08:54:32Z
dc.date.available
2025-10-24T08:54:32Z
dc.date.issued
2020-09-02T08:04:20Z
dc.date.issued
2020-09-02T08:04:20Z
dc.date.issued
2019-10-11
dc.identifier
Ruiz de Porras V, Bystrup B, Cabrero-de las Heras S, Musulén E, Palomero L, Alonso, et al. Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients. Cancers (Basel). 2019 Oct 11;11(10):1540.
dc.identifier
https://hdl.handle.net/11351/5204
dc.identifier
10.3390/cancers11101540
dc.identifier
000498826000137
dc.identifier.uri
http://hdl.handle.net/11351/5204
dc.description.abstract
Colorectal cancer; Cyclin-dependent kinase 5 (Cdk5); Prognostic and predictive biomarker
dc.description.abstract
Cáncer colorrectal; Quinasa dependiente de ciclina 5 (Cdk5); Biomarcador pronóstico y predictivo
dc.description.abstract
Càncer colorectal; Quinasa dependent de ciclina 5 (CDK5); Biomarcador pronòstic i predictiu
dc.description.abstract
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease.
dc.description.abstract
This work has been funded by the ISCIII grants from the Spanish Government, project numbers PI09/01334 and PI12/02228, and the Departament d’Innovació, Universitats i Empresa, Generalitat de Catalunya, project numbers 2014-SGR-1494, 2017-SGR-1705 and 2017-SGR-723. The group from Eva Martinez Balibrea is furthermore funded by the PIE16/00011 and the group from Diego Arango by the PI16/00540 and AC15/00066 grants.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Cancers;11(10)
dc.relation
https://www.mdpi.com/2072-6694/11/10/1540
dc.relation
info:eu-repo/grantAgreement/ES/6PN/PI12%2F02228
dc.relation
info:eu-repo/grantAgreement/ES/6PN/PI09%2F01334
dc.relation
info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00540
dc.relation
info:eu-repo/grantAgreement/ES/PE2013-2016/PIE16%2F00011
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Recte - Càncer
dc.subject
Quinases dependents de ciclina
dc.subject
Marcadors tumorals
dc.subject
DISEASES::Digestive System Diseases::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Digestive System Diseases::Digestive System Diseases::Digestive System Diseases::Digestive System Diseases::Colorectal Neoplasms
dc.subject
CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases::Proline-Directed Protein Kinases::Cyclin-Dependent Kinases::CDC2-CDC28 Kinases::Cyclin-Dependent Kinase 5
dc.subject
CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor
dc.subject
ENFERMEDADES::enfermedades del sistema digestivo::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::enfermedades del sistema digestivo::enfermedades del sistema digestivo::enfermedades del sistema digestivo::enfermedades del sistema digestivo::neoplasias colorrectales
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-serina-treonina cinasas::proteínas cinasas dirigidas por prolina::cinasas dependientes de ciclina::cinasas CDC2-CDC28::cinasa 5 dependiente de la ciclina
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales
dc.title
Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
